BJCT News Alert Bioject Medical Technologies In (BJCT) 0.1100

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bioject Medical Technologies In (BJCT) 0.1100 $BJCT

Global Needle-free Drug Delivery Technologies market 2015-2019: Key Vendors are 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet and Zogenix
PR Newswire Europe - Wed Jan 28, 10:25AM CST
DUBLIN, Jan. 27, 2015 /PRNewswire/ --Research and Markets
ATRS: 2.45 (+0.05)

Global Needle-free Drug Delivery Technologies market 2015-2019 3M, Antares Pharma, Bioject Medical Technologies, Glide Pharmaceutical Technologies, PharmaJet & Zogenix Dominating
M2 - Thu Jan 15, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt6m7j/global) has announced the addition of the "Global Needle-free Drug Delivery Technologies market 2015-2019" report to their offering. The Global Needle-free Drug Delivery Technologies market to grow at a CAGR of 13.5% over the period 2014-2019 This report covers the present scenario and the growth prospects of the Global Needle-free Drug Delivery Technologies market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various needle-free drug delivery systems with active mechanisms for skin permeation such as velocity, ultrasound, iontophoresis, thermo ablation, and electrophoresis. The introduction and enforcement of various laws mandating the use of safety needles/syringes and needle-free devices are one of the major trends in this market. With the introduction and enforcement of such laws, the Healthcare and Pharmaceuticals markets worldwide are now switching to the mandatory use of safety needles/syringes and needle-free devices to help protect those at risk of infection from NSIs and other unsafe injection practices. According to the report, increased safety and efficiency are the key factors responsible for the growth of the market. Needle-free drug delivery systems provide better acceptability, particularly in self-administration settings. Further, the report states that needle-free drug delivery systems are associated with increased technology because of which there is a decrease in the rate of adoption. These devices require training modules and instruction manuals for the users. This mode of drug delivery includes: - Jet Injectors - Transdermal Patches (Microneedles, Nanopatches) Key Vendors - 3M - Antares Pharma - Bioject Medical Technologies - Glide Pharmaceutical Technologies - PharmaJet - Zogenix For more information visit http://www.researchandmarkets.com/research/rt6m7j/global
ATRS: 2.45 (+0.05)

Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines
PRWeb - Fri Dec 19, 8:03AM CST
Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into an agreement with Immunomic Therapeutics, Inc. ("ITI" for ITI to use the Bioject's Biojector(R)-2000 needle-free injection device with its LAMP™ vaccine platform.

Global Insulin Delivery Devices Market 2014-2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers
M2 - Tue Jun 24, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6qt2hc/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. 'Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers' looks at the market, competitive landscape, and trends for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment's pipeline products and gives details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Key geographies: the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil. - Information on market size for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories. - Annualized market revenue data forecast to 2019 and company share data for 2012. - Qualitative analysis of key trends in the insulin delivery devices market. - Information on the competitive landscape and the leading technologies of key players: Novo Nordisk A/S, Medtronic, Inc., Sanofi, Eli Lilly and Company, Becton, Dickinson and Company, Animas Corporation, Insulet Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories. - Information on reimbursement trends and market access for key countries. Reasons to buy - Develop business strategies by understanding the trends and developments driving the global insulin delivery devices market. - Design and enhance your product development, marketing, and sales strategies. - Exploit M&A opportunities by identifying the market players with the most innovative pipelines. - Develop market-entry and market-expansion strategies. - Identify the key players best positioned to take advantage of the emerging market opportunities. - Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return. - Identify, understand and capitalize on the next big thing in the insulin delivery devices market landscape. - Make more informed business decisions from insightful and in-depth analysis of the global insulin delivery devices market and the factors shaping it. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape 11 Global Insulin Delivery Devices Market: Product Pipeline Analysis 12 Global Insulin Delivery Devices Market: Consolidation Landscape 13 Appendix Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/6q...n_delivery
ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03), ATRS: 2.45 (+0.05)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 4

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 5

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 7

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 3

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 2

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Tilray Brands Achieves Exceptional Performance in Q1 2025

Updated Category News Views 226

Tilray Brands Delivers Record Q1 Revenue Tilray Brands (NASDAQ: TLRY) has announced an impressive net revenue of $200 million for its first fiscal quarter, showcasing a remarkable 13% increase from the previous year. The significant boost can largely be attributed to the exponential growth within its beverage sector, including both traditional craft beers and innovative...

Continue Reading
Exor N.V. Announces Impressive Growth and Strategic Moves

Updated Category News Views 361

Exor N.V. Reports Robust Year-End Performance Exor N.V. has once again demonstrated significant growth and strategic financial management through its latest annual results. The company reported an impressive 9% growth in Net Asset Value (NAV) per share for the fiscal year, reaching €38.2 billion by year-end. This financial achievement reflects Exor's robust operational...

Continue Reading
Integral Ad Science Faces Legal Challenge – Join the Action

Updated Category News Views 102

Integral Ad Science Holding Corp. Faces Securities Fraud Allegations Levi & Korsinsky, LLP is reaching out to the investors of Integral Ad Science Holding Corp. (NASDAQ: IAS), as there is an ongoing class action securities lawsuit that could allow affected investors to recover losses. Understanding the Class Action Details This class action lawsuit aims to represent those...

Continue Reading
Innovative Oncology Solutions Unveiled by Powered Research

Updated Category News Views 132

Expanding Horizons: Powered Research's New Oncology Services For over a decade, Powered Research has earned its reputation as a premier preclinical contract research organization (CRO), particularly in the field of ophthalmology. Today, the company takes a monumental step forward by launching an extensive suite of oncology preclinical services. This new direction is set...

Continue Reading
Discover Why Jim Cramer Recommends Dominion Energy Stock

Updated Category News Views 65

Jim Cramer Sees Potential in Dominion Energy In a recent episode of CNBC's programming, well-known financial commentator Jim Cramer highlighted Dominion Energy, Inc. (D) as a promising buy. He stated, "We need cheap power," which underscores the increasing demand for affordable energy solutions in today's unpredictable market landscape. Analyst Ratings for Dominion Energy...

Continue Reading